The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 19, 2018

Filed:

Apr. 29, 2014
Applicants:

Ogd2 Pharma, Nantes, FR;

Universite DE Nantes, Nantes Cedex, FR;

Inventors:

Stephane Birkle, Nantes, FR;

Denis Cochonneau, Nantes, FR;

Mylene Dorvillius, Nantes, FR;

Jean-Marc Le Doussal, Nantes, FR;

Mickael Terme, Nantes, FR;

Assignees:

OGD2 PHARMA, Nantes, FR;

UNIVERSITE DE NANTES, Nantes, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/30 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3084 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/73 (2013.01);
Abstract

An antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer, a pharmaceutical composition including the antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, the method including administering the antibody to the patient. A method for diagnosing a CSC, the use of the O-acetylated-GD2 ganglioside as a biomarker of CSC cancer, and a method for predicting the response of a subject affected with CSC cancer to a treatment with the antibody or the composition are also described.


Find Patent Forward Citations

Loading…